Streetbeat News

BHVN

Biohaven Ltd.

https://www.biohaven.com/

Industry

Biotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Open

28.76

Mkt cap

Volume

654K

High

29.65

P/E Ratio

-3.14

52-wk high

60.46

Low

28.52

Div yield

N/A

52-wk low

26.80

Biohaven announced the FDA's acceptance and Priority Review of its NDA for troriluzole in treating spinocerebellar ataxia, with a PDUFA date expected in Q3 2025. The company reported $489 million in cash and equivalents as of the end of 2024.

Portfolio Pulse from

March 03, 2025 | 12:45 pm

Biohaven's valuation has significantly increased following Pfizer's acquisition, rising from $300M to over $4B. Despite this, further upside is expected due to promising clinical assets with key catalysts anticipated in 2025.

Portfolio Pulse from

February 28, 2025 | 10:30 am

Biohaven's stock surged over 11% following a positive regulatory development for its leading investigational drug, bringing it closer to potential approval.

Portfolio Pulse from

February 12, 2025 | 12:00 am

Biohaven's NDA for Troriluzole in spinocerebellar ataxia has been accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. Additionally, BHV-7000 is being studied for bipolar disorder and MDD, with data expected in 2025. The global MDD treatment market is projected to reach $14.96 billion by 2032.

Portfolio Pulse from

February 11, 2025 | 11:00 pm

Biohaven's experimental drug for spinal muscular atrophy showed improvement in motor function but did not achieve statistical significance in a late-stage study.

Portfolio Pulse from

November 25, 2024 | 1:00 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Biohaven (NYSE:BHVN).

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 4:15 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Scholar Rock Holding (SRRK) saw a massive increase of 198.1%, while Trevena (TRVN) experienced a sharp decline of 45.5%. Other notable gainers include LogicMark (LGMK) and Biohaven (BHVN), while Entero Therapeutics (ENTO) and Onconetix (ONCO) were among the losers.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 12:08 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Biohaven (NYSE:BHVN).

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 1:38 pm

JP Morgan analyst Tessa Romero has maintained an Overweight rating on Biohaven (NYSE:BHVN) and raised the price target from $55 to $68.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:54 pm

Acuity Brands, ReposiTrak, McCormick, Biohaven, and Nike are stocks to watch as U.S. stock futures trade lower. Acuity Brands and McCormick are set to release earnings, ReposiTrak reported strong results and increased dividends, Biohaven announced a public offering, and Nike's earnings are anticipated.

Portfolio Pulse from Avi Kapoor

October 01, 2024 | 6:47 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.